DNA microarray-based resonance light scattering assay for multiplexed detection of DNA mutation in papillary thyroid cancer
Highly accurate analysis of single-nucleotide polymorphisms (SNPs) plays an important role in both disease diagnostics and personalized medicine development. In this work, a DNA microarray-based resonance light scattering (RLS) assay has been developed for multiplexed detection of papillary thyroid carcinoma (PTC) related mutation points including BRAFV600E (t1m), NRAS codon 61 (t2m), TERT promoter g.1295228 (t31m) and TERT promoter g.1295250 (t32m) with high sensitivity and selectivity by the attachment of polyvalent ssDNA modified 13 nm gold nanoparticles (ssDNAsGNPs) followed by silver deposition for signal enhancement. The microarray-based RLS assay provides a detection limit (S/N = 3) at the sub-nanomolar level for the target ssDNAs and determines allele frequencies as low as 0.2% for t1m, 0.2% for t2m, 0.5% for t31m, and 0.5% for t32m in the cocktail of target ssDNAs, respectively. The practicability of the DNA microarray-based RLS assay is demonstrated by profiling of t2m in 50 clinical thyroid tissue samples of PTC patients, and satisfactory results are obtained.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
---|---|
Enthalten in: |
The Analyst - 143(2018), 4 vom: 12. Feb., Seite 914-919 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Yaoqi [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 03.01.2019 Date Revised 03.01.2019 published: Print Citation Status MEDLINE |
---|
doi: |
10.1039/c7an01773a |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM280242689 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM280242689 | ||
003 | DE-627 | ||
005 | 20231225024905.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1039/c7an01773a |2 doi | |
028 | 5 | 2 | |a pubmed24n0934.xml |
035 | |a (DE-627)NLM280242689 | ||
035 | |a (NLM)29362729 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Yaoqi |e verfasserin |4 aut | |
245 | 1 | 0 | |a DNA microarray-based resonance light scattering assay for multiplexed detection of DNA mutation in papillary thyroid cancer |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.01.2019 | ||
500 | |a Date Revised 03.01.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Highly accurate analysis of single-nucleotide polymorphisms (SNPs) plays an important role in both disease diagnostics and personalized medicine development. In this work, a DNA microarray-based resonance light scattering (RLS) assay has been developed for multiplexed detection of papillary thyroid carcinoma (PTC) related mutation points including BRAFV600E (t1m), NRAS codon 61 (t2m), TERT promoter g.1295228 (t31m) and TERT promoter g.1295250 (t32m) with high sensitivity and selectivity by the attachment of polyvalent ssDNA modified 13 nm gold nanoparticles (ssDNAsGNPs) followed by silver deposition for signal enhancement. The microarray-based RLS assay provides a detection limit (S/N = 3) at the sub-nanomolar level for the target ssDNAs and determines allele frequencies as low as 0.2% for t1m, 0.2% for t2m, 0.5% for t31m, and 0.5% for t32m in the cocktail of target ssDNAs, respectively. The practicability of the DNA microarray-based RLS assay is demonstrated by profiling of t2m in 50 clinical thyroid tissue samples of PTC patients, and satisfactory results are obtained | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a DNA, Single-Stranded |2 NLM | |
650 | 7 | |a Membrane Proteins |2 NLM | |
650 | 7 | |a Gold |2 NLM | |
650 | 7 | |a 7440-57-5 |2 NLM | |
650 | 7 | |a BRAF protein, human |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
650 | 7 | |a TERT protein, human |2 NLM | |
650 | 7 | |a EC 2.7.7.49 |2 NLM | |
650 | 7 | |a Telomerase |2 NLM | |
650 | 7 | |a EC 2.7.7.49 |2 NLM | |
650 | 7 | |a GTP Phosphohydrolases |2 NLM | |
650 | 7 | |a EC 3.6.1.- |2 NLM | |
650 | 7 | |a NRAS protein, human |2 NLM | |
650 | 7 | |a EC 3.6.1.- |2 NLM | |
700 | 1 | |a Gao, Jiaxue |e verfasserin |4 aut | |
700 | 1 | |a Meng, Xianying |e verfasserin |4 aut | |
700 | 1 | |a Wang, Zhenxin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Analyst |d 1945 |g 143(2018), 4 vom: 12. Feb., Seite 914-919 |w (DE-627)NLM000012653 |x 1364-5528 |7 nnns |
773 | 1 | 8 | |g volume:143 |g year:2018 |g number:4 |g day:12 |g month:02 |g pages:914-919 |
856 | 4 | 0 | |u http://dx.doi.org/10.1039/c7an01773a |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 143 |j 2018 |e 4 |b 12 |c 02 |h 914-919 |